Log in

2410 TYK Medicines, Inc. HKEX · China

TYK Medicines (2410) news

TYK Medicines, Inc. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2410, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest TYK Medicines news

We have not published a story on TYK Medicines yet. When there is news, it will appear here.

Questions about TYK Medicines

What is the ticker symbol of TYK Medicines?

TYK Medicines, Inc. trades under the ticker 2410 on HKEX.

Where is TYK Medicines listed?

TYK Medicines, Inc. is listed on HKEX.

Which country or territory is TYK Medicines listed under?

Our directory records TYK Medicines, Inc. under China.

What does TYK Medicines do?

Our directory classifies TYK Medicines, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of TYK Medicines?

The ISIN recorded for TYK Medicines, Inc. is CNE100006L34.

Does aibio.space cover TYK Medicines?

aibio.space lists TYK Medicines, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to TYK Medicines?

Companies in our directory listed in the same country and business area as TYK Medicines: China Resources Boya Bio-pharmaceutical Group Co., Zhangzhou Pientzehuang Pharmaceutical Co., Zhejiang Ausun Pharmaceutical Co., Enwei Pharmaceutical Co., Wanbangde Pharmaceutical Holding Group Co., Shanghai Yizhong Pharmaceutical Co..

Investor discussion: TYK Medicines

Members talk about TYK Medicines (2410). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at TYK Medicines, newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: LAPSE OF SUBSCRIPTION AGREEMENT IN RELATION TO THE ISSUE OF H SHARES UNDER GENERAL MANDATE. Source

  2. Financings

    Share or debt issue: EXTENSION OF LONG STOP DATE IN RELATION TO THE ISSUE OF H SHARES UNDER GENERAL MANDATE. Source

  3. Legal

    Legal proceedings: ANNOUNCEMENT ON LEGAL PROCEEDINGS RELATING TO THE COMPANY. Source

  4. Financings

    Share or debt issue: (1) LICENSE AND COLLABORATION WITH QILU; AND (2) ISSUE OF H SHARES UNDER GENERAL MANDATE. Source

  5. Financings

    Share or debt issue: (1) GENERAL MANDATE TO ISSUE SHARES; AND (2) NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026. Source

  6. Mergers

    Transaction under the Listing Rules: DISCLOSEABLE TRANSACTIONS - SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS; INVESTMENT AND REDEMPTION OF FUND INTEREST; AND UPDATE IN USE OF IDLE FUNDS FROM THE GLOBAL OFFERING. Source

  7. Financings

    Share or debt issue: COMPLETION OF PLACING OF NEW H SHARES UNDER THE GENERAL MANDATE. Source

  8. Financings

    Share or debt issue: PLACING OF NEW H SHARES UNDER GENERAL MANDATE. Source

Press releases

Headlines of TYK Medicines's own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    ARTICLES OF ASSOCIATION

  2. HKEXnews

    POLL RESULTS OF 2026 SECOND EXTRAORDINARY GENERAL MEETING HELD ON OCTOBER 16, 2026

  3. HKEXnews

    NOTICE OF THE SECOND EXTRAORDINARY GENERAL MEETING OF 2026

  4. HKEXnews

    LAPSE OF SUBSCRIPTION AGREEMENT IN RELATION TO THE ISSUE OF H SHARES UNDER GENERAL MANDATE

  5. HKEXnews

    BOOK CLOSURE PERIOD FOR 2026 SECOND EXTRAORDINARY GENERAL MEETING

  6. HKEXnews

    Notification Letter to Non-registered H Shareholders and Reply Form - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications

  7. HKEXnews

    Notification Letter to Registered H Shareholders and Reply Form - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications

  8. HKEXnews

    VOLUNTARY ANNOUNCEMENT - FURTHER INCREASE IN SHAREHOLDING IN THE COMPANY BY THE CHAIRMAN, EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER

  9. HKEXnews

    VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING IN THE COMPANY BY THE CHAIRMAN, EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER

  10. HKEXnews

    VOLUNTARY ANNOUNCEMENT - MARKETING APPLICATION FOR ASANDEUTERTINIB MESYLATE TABLETS (TY-9591) HAS OBTAINED CONDITIONAL APPROVAL GRANTED BY NMPA

  11. HKEXnews

    EXTENSION OF LONG STOP DATE IN RELATION TO THE ISSUE OF H SHARES UNDER GENERAL MANDATE

  12. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026; RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

  13. HKEXnews

    (1) RESIGNATION OF NON-EXECUTIVE DIRECTOR AND CHANGE OF AUTHORIZED REPRESENTATIVE; AND (2) PROPOSED RE-ELECTION OF DIRECTORS

  14. HKEXnews

    ANNOUNCEMENT ON LEGAL PROCEEDINGS RELATING TO THE COMPANY

  15. HKEXnews

    (1) LICENSE AND COLLABORATION WITH QILU; AND (2) ISSUE OF H SHARES UNDER GENERAL MANDATE

  16. HKEXnews

    POLL RESULTS OF 2026 FIRST EXTRAORDINARY GENERAL MEETING HELD ON JULY 15, 2026

  17. HKEXnews

    NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026

  18. HKEXnews

    (1) GENERAL MANDATE TO ISSUE SHARES; AND (2) NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026

  19. HKEXnews

    BOOK CLOSURE PERIOD FOR EXTRAORDINARY GENERAL MEETING

  20. HKEXnews

    POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING HELD ON JUNE 23, 2026

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2410 on TradingView.

Listing details

TYK Medicines, Inc. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2410, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
TYK Medicines, Inc.
Ticker
2410
Listing
HKEX
Country or territory
China
Business scope
Pharmaceuticals: Major
ISIN
CNE100006L34
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.